Key Takeaways

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later.

The chemotherapy group experienced four times more severe adverse events compared to hormonal therapy alone.

Use of a non-commercial genomic assay and limited ability to adjust for competing mortality causes may limit applicability to clinical practice.

Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant chemotherapy, which caused a high rate of severe toxicity, according to a large randomized trial.

Overall survival (OS) at 4 and 8 years was 90.5% and 72.7% in patients who received chemotherapy in addition to hormonal therapy versus 89.3% and 68.3% in the gro

See Full Page